Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Senate Finance Committee investigated Gilead's $84,000 Sovaldi pricing, finding the company set a revenue-driven pricing strategy from the start that…
Over the last five years, Gilead Sciences made a whopping $58.5B from its HCV franchise — the Pharmasset acquisition paid off quite nicely despite initial Wall…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Gilead Sciences acquired Pharmasset for $11.2 billion in cash, gaining sofosbuvir (PSI-7977), a nucleotide analog for hepatitis C treatment.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Pharmasset Inc. (this deal) | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
| Gilead Sciences Inc. / Myogen Inc. | 2006 | $2.5B | 62 |
← Browse all deals · How we score deals
More: 2011 deals · Gilead Sciences Inc. deals · Infectious Disease deals